Rezolute announces presentation at the retina society 55th annual scientific meeting

Redwood city, calif., oct. 20, 2022 (globe newswire) -- rezolute, inc. (nasdaq: rzlt), a clinical-stage biopharmaceutical company dedicated to developing transformative therapies with the potential to shift the treatment paradigms of devastating metabolic diseases, today announced it will present clinical data from its phase 1b multiple-ascending dose (mad) study of rz402 in diabetic macular edema (dme) in a podium presentation at the retina society 55th annual scientific meeting being held november 2-5, 2022 in pasadena, ca.
RZLT Ratings Summary
RZLT Quant Ranking